The importance of reducing cardiovascular risk in patients with type 2 diabetes
This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information
PC-GB-104395 April 2021
Managing patients with type 2 diabetes—a cardiometabolic pathway for a cardiovascular risk reduction approach
This webinar has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice. Products are discussed.
View Jardiance®(empagliflozin) prescribing and adverse event reporting information
PC-GB-103199 March 2021
Chronic obstructive pulmonary disease: managing breathlessness
This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice. The webinar is intended for UK healthcare professionals.
PC-GB-103138 Date of preparation: November 2020
What are our options for children with severe asthma?
This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice. The webinar is intended for UK healthcare professionals.
PC-GB-103140 Date of preparation: November 2020
The appropriate use of inhaled corticosteroids (ICS) in COPD
This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice. The webinar is intended for UK healthcare professionals.
PC-GB-103139 Date of preparation: November 2020
Respimat® Soft Mist reusable inhaler: patient benefits and environmental impact
This promotional animation has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines in Practice.
View prescribing information
PC-GB-103871 February 2021
Prescribing a dipeptidyl peptidase-4 inhibitor in people with type 2 diabetes and comorbidities
This animation has been commissioned and funded by Boehringer Ingelheim Limited and developed in partnership with Guidelines in Practice.
Five things you need to know about… bronchiectasis
In the first of a new series of videos, Dr Kevin Gruffydd-Jones highlights five things you need to know about bronchiectasis
NICE guidance on respiratory conditions and COVID-19: 5-minute video
Dr Kevin Gruffydd-Jones highlights important things you need to know about managing respiratory conditions in a COVID-19 context
Death certification in COVID-19: 5-minute video
Dr Toni Hazell highlights important things you need to know about changes to death certification processes during the COVID-19 outbreak
Soprobec (beclometasone dipropionate) pMDI
This formulary decision guide was developed from content provided by Glenmark Pharmaceuticals Europe Ltd in a format developed by Guidelines in Practice.
View prescribing information
PP-UK-SOP-0130 V2 March 2021
PROSTAP® DCS (leuprorelin acetate)
This formulary decision guide was developed by Guidelines in Practice based on content and funding provided by Takeda UK Ltd. Information intended for healthcare professionals only.
View prescribing information here
C-APROM/UK/LEU/0075 February 2021
Nutramigen* PURAMINO*
This formulary decision guide was developed from content provided by Mead Johnson Nutrition in a format developed by Guidelines inPractice.
RB-M-18261 October 2020
Nutramigen* 1, 2 & 3 LGG®
This formulary decision guide was developed from content provided by Mead Johnson Nutrition in a format developed by Guidelines in Practice.
RB-M-18259 October 2020
Prostap® DCS (leuprorelin acetate)—a 3-monthly gonadotrophin-releasing hormone (GnRH) agonist treatment for breast cancer
Information intended for UK healthcare professionals only. This round-table discussion supplement has been commissioned and funded by Takeda UK Ltd and developed in partnership with Guidelines in Practice.
View prescribing information
C-APROM/UK/PRS/0152
Date of preparation: April 2021
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse event reporting information
PC-GB-103451 Date of preparation: January 2021
The re-usable Respimat® Soft Mist inhaler
This promotional supplement has been commissioned and funded by Boehringer Ingelheim Ltd and developed in partnership with Guidelines in Practice.
View prescribing information
PC-GB-103142 November 2020
Real-world usage study and survey of oral bowel cleansing for colonoscopy in Dudley, UK
This supplement has been commissioned by Norgine Pharmaceuticals Limited and contains promotional information. Information for healthcare professionals only.
Click here for PLENVU® (macrogol 3350, sodium ascorbate, ascorbic acid, sodium sulfate anhydrous, potassium chloride, sodium chloride) Prescribing and Adverse Event Reporting.
Click here for MOVIPREP® ((macrogol 3350, sodium sulfate anhydrous, ascorbic acid, sodium ascorbate, sodium chloride, and potassium chloride) Prescribing and Adverse Event Reporting.
Click here for KLEAN-PREP (macrogol 3350, anhydrous sodium sulfate, sodium bicarbonate, sodium chloride, potassium chloride) Prescribing and Adverse Event Reporting.
UK-GE-PLV-2000027
Date of preparation: February 2021
Recommending emollients for patients with atopic dermatitis or dry skin conditions
This supplement has been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines.
Date of preparation: January 2021
Practical tips for maintaining asthma care prompted by a supply issue during the COVID-19 pandemic
This supplement has been commissioned and funded by Glenmark Pharmaceuticals Europe Ltd and developed in partnership with Guidelines in Practice.
View prescribing information
PP-UK-SOP-0129 December 2020
Showcasing local best practice in diabetes
This Guidelines in Practice supplement aims to showcase local best practice in the diagnosis and management of diabetes. The supplement includes articles from three local initiatives that have developed their own guidance or demonstrated improvements in different areas of diabetes care:
An optimised patient pathway for the treatment of heterosexual patients with infertility
This supplement has been commissioned and funded by Merck Serono Ltd and developed in partnership with Guidelines in Practice.
Identification and management of patients with malnutrition
This supplement has been commissioned and funded by Alliance Pharmaceuticals Ltd and developed in partnership with Guidelines in Practice.
Guideline for the managed introduction of biosimilar basal insulin
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
Implementing the Guidelines algorithm on managing obesity in primary care
Guidelines in Practice approached Novo Nordisk Ltd for an educational grant to support the production of an implementation checklist. Information intended for UK healthcare professionals only.
Date of preparation: January 2021
Implementing the Guidelines algorithm on identifying and managing allergic rhinitis in the asthma population
Information intended for healthcare professionals only.
Implementing the Primary Care Dermatology Society guideline and primary care treatment pathway for acne vulgaris
Information intended for healthcare professionals only.
NICE Technology Appraisal 694: Bempedoic acid▼ with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
The production of this Guidelines card has been commissioned and funded by Daiichi Sankyo UK.
View Bempedoic acid (Nilemdo®▼) & Bempedoic acid and ezetimibe (Nustendi®▼) prescribing and adverse event reporting information
BEM/21/0374 May 2021
Romosozumab▼ (Evenity®) 105mg solution for injection in prefilled pen SMC2280
The production of this Guidelines card has been commissioned by UCB Pharma Ltd.
Amgen and UCB Pharma Ltd are co-developing Evenity®.
View prescribing information and adverse event reporting
UK-P-RM-OP-2000095 December 2020
NICE Technology Appraisal 672: ▼Brolucizumab for treating wet age-related macular degeneration
The printing of this Guidelines summary card has been commissioned by Novartis Pharmaceuticals UK Ltd. Information intended for UK healthcare professionals only.
Click here for Prescribing information and Adverse Event Reporting.
MLR ID 103903
Date of preparation: February 2021
Actinic keratosis (syn. solar keratosis)—Primary Care Dermatology Society
The production, printing, and distribution of this Guidelines reprint has been commissioned and funded by Almirall Ltd. Information intended for UK healthcare professionals only.
UK-ATK-2100001 March 2021
Dr Girish Gupta–Lunchtime sponsored symposium: Managing acne with topical therapies
This video has been commissioned and funded by Galderma and was recorded for Guidelines Live 2020. Please see the bottom of the page for the full disclaimer.
UKI-EDG-2100012 Date of preparation: March 2021